Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of BI 1015550 in Japanese healthy male subjects
jRCT2071230092Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of nerandomilast (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: AUC0-∞ of BI 1015550 in plasma and Cmax of BI 1015550 in plasma. Started Nov 2023; status: completed.
02
Drugs
nerandomilast
Beyond the preview
Go deeper on jRCT2071230092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230092.